ENANTA PHARMACEUTICALS INCENTAEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 9.20% | 1.9M | ▼ -0.20pp | 2024-01-24 |
| The Vanguard Group | 8.52% | 1.8M | — | 2024-02-13 |
| Armistice Capital, LLC | 4.72% | 1.0M | ▼ -5.08pp | 2024-11-14 |
| Millennium Management LLC | 3.50% | 731.3K | ▼ -2.70pp | 2024-10-17 |
| STATE STREET CORPORATION | 2.02% | 29.3K | — | 2024-01-22 |
| Farallon Capital Partners, L.P. | 1.80% | 379.2K | — | 2024-01-26 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-02-12 | Luly Jay R. | President and CEO | Grant | 4.8K | $0.00 | $0 |
| 2026-02-12 | Luly Jay R. | President and CEO | Grant | 15.2K | $0.00 | $0 |
| 2026-02-12 | Or Yat Sun | Chief Scientific Officer | Grant | 1.6K | $0.00 | $0 |
| 2026-02-12 | Or Yat Sun | Chief Scientific Officer | Grant | 5.2K | $0.00 | $0 |
| 2026-02-12 | Kieffer Tara Lynn | Chief Product Strategy Officer | Grant | 1.6K | $0.00 | $0 |
| 2026-02-12 | Kieffer Tara Lynn | Chief Product Strategy Officer | Grant | 5.0K | $0.00 | $0 |
| 2026-02-12 | Kowalsky Matthew Paul | Chief Legal Officer | Grant | 1.3K | $0.00 | $0 |
| 2026-02-12 | Kowalsky Matthew Paul | Chief Legal Officer | Grant | 4.2K | $0.00 | $0 |
| 2026-02-12 | Rottinghaus Scott T. | Chief Medical Officer | Grant | 1.6K | $0.00 | $0 |
| 2026-02-12 | Rottinghaus Scott T. | Chief Medical Officer | Grant | 5.2K | $0.00 | $0 |
1–10 of 12
Page 1 / 2